Back to results
US 2019/0169620 A1Published application
Treatment of HER2-Dependent Cancers by SORL1 Inhibition
AssigneeTurun Yliopisto
InventorsMika PIETILÄ, Johanna IVASKA, Pranshu SAHGAL
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the field of cancer therapeutics. Exemplary embodiments relate to agents that inhibit expression of SORL1, a gene encoding for Sortilin related protein family-A (SORLA) or the function of SORLA protein, a multifunctional protein belonging to sortilin and LDL-receptor families, and to methods for their use in treating HER2-dependent cancers.
Claims20
A composition comprising:
- a SORL1 inhibiting agent, selected for treating HER2-dependent cancer;
- and
- a drug selected from the group consisting of cationic amphiphilic drugs (CAD) and HER2-targeted drugs.
(canceled)
(canceled)
Method for treating HER2-dependent cancer, the method comprising:
- administering a therapeutically effective amount of an SORL1 inhibiting agent to a subject in need thereof.
Dependencies are inferred from the claim text.